CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate ...
I covered Beam Therapeutics (BEAM) in April last year, when the stock had a market cap of $3.7bn. Today, despite some derisking events, it has a market cap of $2.6bn. The stock price has fallen 30% as ...
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...
Beam Therapeutics' pipeline progress remains slow, with BEAM-101 still recruiting and CAR-T programs discontinued to reduce cash burn. Gene therapy markets targeted by Beam, such as SCD and AATD, are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback